[Social9_Share]

Epilepsy Research UK has joined forces with Angelini Pharma to commission a study that will use large-scale NHS clinical data records to understand and predict important clinical outcomes in refractory epilepsy. The collaboration between the two funders and the successful applicant will bring together the expertise to support a pilot study that will underpin future development in this area and accelerate innovations in the treatment and care of people living with uncontrolled epilepsy.

Applications are invited for high-quality pilot study proposals of up to £200,000 to support a research project lasting a maximum of two years. Proposals will identify sources of clinical data that can be organised and used to characterise predictors of epilepsy to support advances in clinical interventions and pathways. We encourage multidisciplinary proposals, with an emphasis on the long-term sustainability of the dataset and with the potential for scalability.

SCOPE OF THE CALL

Applications are welcomed for health data research that includes all of the following components:

1. Identification of relevant patient dataset(s) such as NHS (National Health Service) electronic health records or existing cohorts
2. Organisation, design, and manipulation of data using novel or existing health data research analytic tools or programmes, with emphasis on future sustainability and scalability as a data resource
3. Characterisation of predictors of refractory epilepsy using predefined clinically relevant outcomes to understand and predict refractory epilepsy and accelerate innovations in the treatment and care

APPLICATIONS WILL CLOSE AT 4PM ON 16TH MAY 2022.

More information and application details – https://epilepsyresearch.org.uk/angelini-innovations-in-healthcare/

 

SOURCE: epilepsyresearch.org.uk

RECENT NEWS